Hawaii 2023 Regular Session

Hawaii House Bill HB1337

Introduced
1/25/23  

Caption

Relating To Psilocybin.

Impact

The working group established by this bill will explore the medicinal and therapeutic uses of psilocybin, with a focus on laws and regulations governing its use. The group will analyze data from other states that have legalized medicinal psilocybin, such as Oregon and Colorado, to inform their findings. By reviewing existing laws and conducting studies, the working group aims to recommend a long-term strategic plan to ensure safe and affordable access to psilocybin products for adults aged 21 and over. This bill seeks to proactively address the mental health treatment crisis and may pave the way for new legislation on psilocybin in Hawaii.

Summary

House Bill 1337, introduced in Hawaii's legislative session, seeks to address significant issues surrounding mental health treatment by establishing a therapeutic psilocybin working group. The bill underscores the growing recognition of the detrimental effects of untreated mental health conditions within the population, exacerbated by a shortage of qualified mental health professionals. Psilocybin, a naturally occurring compound found in certain mushrooms, has shown promise in treating a range of mental health disorders, including post-traumatic stress disorder (PTSD), depression, anxiety, and distress related to end-of-life scenarios. Recognizing its potential, the U.S. Food and Drug Administration has labeled psilocybin-assisted therapy for treatment-resistant depression as a 'breakthrough therapy'.

Contention

While supporters of HB 1337 argue that it represents a significant step forward in exploring innovative treatment options for mental health issues, detractors may raise concerns about the implications of legalizing psilocybin. Discussions surrounding the bill may touch on public health considerations, the stigma surrounding psychedelic substances, and the need for comprehensive research on the safety and efficacy of psilocybin therapies. Balancing the need for enhanced mental health treatment options with community concerns about drug regulation will likely be a central point of contention as the bill advances through the legislative process.

Companion Bills

HI SB1454

Same As Relating To Psilocybin.

Similar Bills

HI SB3160

Relating To Psilocybin.

HI HB2400

Relating To Psilocybin.

HI SR88

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Develop A Longterm Strategic Plan, Should Food And Drug Administration Approval For Medical Use Be Obtained, To Enable The Availability Of Therapeutic Psilocybin Or Psilocybin-based Products That Are Safe, Accessible, And Affordable For Adults Twenty-one Years Of Age Or Older.

HI SCR100

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Develop A Long-term Strategic Plan, Should Food And Drug Administration Approval For Medical Use Be Obtained, To Enable The Availability Of Therapeutic Psilocybin Or Psilocybin-based Products That Are Safe, Accessible, And Affordable For Adults Twenty-one Years Of Age Or Older.

HI SB1454

Relating To Psilocybin.

HI SB1454

Relating To Psilocybin.

HI SR153

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group.

HI HR206

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group.